India’s First Advanced Homoeopathy Virology lab Opens in Kolkata

IMT News Desk
IMT News Desk
· 2 min read
Globuli Drug Medical Medicine Homeopathy Beads
The Union Minister of State for AYUSH (Independent Charge) Shripad Yesso Naik inaugurated India’s first State of art virology laboratory at Dr. Anjali Chatterjee Regional Research Institute for Homoeopathy in Kolkata today. In his inaugural address the Minister appreciated the popularity of Homoeopathy in West Bengal. Naik said that this laboratory has been established to develop new drugs and technologies in Homoeopathy to combat emerging challenges of viral diseases. In this context the Minister expressed his satisfaction of recognising this laboratory by the Calcutta University to undertake research work of the PhD students in Homoeopathy.
The laboratory, established at a cost of Rs. 8 crore is the only one in India for conducting basic and fundamental research in Homoeopathy for viral diseases like influenza, Japanese encephalitis, dengue, chickunguniya and swine flu. New drugs and technologies would also be developed here to combat emerging challenges of viral diseases.
The AYUSH Minister also appreciated efforts of the National Institute of Homoeopathy (NIH), Kolkata which is imparting higher education and training in homoeopathy under the Ministry of AYUSH and urged that both the institutes could forge an active collaboration on practical training to the students and research scholars in virus research, both in laboratory and in the field jointly.
Shripad Naik expressed happiness over Council’s initiatives of establishing a Centre of Excellence in Fundamental Research in Homoeopathy at IIEST, Howrah to undertake fundamental research studies in homoeopathy with an interdisciplinary approach. This institute has undertaken several clinical research studies like autism, psoriasis, vitiligo, breast cancer, hypertension, migraine etc along with proving of new drugs in homoeopathy with their clinical validations. About 400 patients are being treated daily through OPD services and AYUSH outreach services being provided in villages too.
Dr. V.K. Gupta, Chairman Scientific Advisory Committee, CCRH, New Delhi, Prof. Ajoy Kumar Roy, Director, IIEST, Shibpur, Dr. Rathin  Chakravarty, Member, Scientific Advisory Committee, CCRH, New Delhi, Dr. Raj K. Manchanda, Director General, CCRH, New Delhi among eminent scientists were also present on the occasion.

Read Next

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk
Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk